Where can I listen to this podcast?

This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

No, this podcast does not typically feature guests.

The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

Claim This Podcast

by AD/PD™ on UNLOK

17 episodes

Updated Daily

Accepts GuestsHas Sponsors

Podcast Authority

Beta

PoorBased on show quality, social media presence, reviews, charts, and more

Quality24

Social0

YouTube82

Engagement0

Learn more

Podcast Overview

AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer's, Parkinson’s, and related neurodegenerative diseases. The "AD/PD™ Session Spotlight" series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes. Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.

Language

🇺🇲

Publishing Since

4/17/2025

Visit Website View on Apple Podcasts RSS Feed

🇺🇸 Charts #3

Outreach generated

Apple 142

Spotify 827

Instant mention tracking

Perfect fit!

Unlock The Full Podcast Authority Score Report

See how your podcast performs across key metrics

Podcast Authority

Beta

PoorBased on show quality, social media presence, reviews, charts, and more

Quality24

Social0

YouTube82

Engagement0

Learn more

Excellent Areas

Good Performance

Growth Opportunities

excellent

Episode Length

19 minutes

Performing excellently!

good

Publishing Consistency

Every 13 days

Recommendations available

Unlock the full report to see detailed tips

poor

Episode Thumbnails

Recommendations available

Unlock the full report to see detailed tips

+16 More Metrics

Unlock comprehensive insights including:

• YouTube presence analysis
• Social media reach metrics
• RSS compliance scoring
• Podcast 2.0 features
• Technical standards

What's Included in Your Full Report

Detailed Analytics

Complete breakdown of all 19 authority metrics
Personalized recommendations for each metric
Industry benchmarks and comparisons
Technical RSS feed analysis and compliance scoring

Growth Strategies

Step-by-step action plans for improvement
Quick wins to boost your score immediately
Pro tips from successful podcasters

Get your free podcast insights report

See how your show performs across every key metric

Instant delivery

No spam

Attract Better Guests

High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.

Secure Sponsorships

Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.

Grow Your Audience

Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.

Reach the team behind The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

Verified contact details for this show aren't on file yet — sign up to get notified when they land.

Recent Episodes

August 6, 2026

Neuropathology in the Biomarker Age & Sleep in Lewy Body Disease, AD/PD™ Session Spotlight

In this episode, we spotlight Plenary Lectures 01 and 02 from the AD/PD™ 2026 International Conference, held on March 17, 2026. The lectures were chaired by Sandra O. Moose (USA) and Prof. Gabriel Gold (Switzerland). Plenary Lecture 01, "Understanding Neurodegenerative Diseases Today: Lessons from Clinicopathological Correlations and the Ongoing Role of Neuropathology in the Biomarker Age," was presented by Prof. Lea Grinberg (USA). Plenary Lecture 02, the Eric N. Birch Lecture, "Key Sleep Issues Pertinent to the Development and Progression of Neurodegeneration in Lewy Body Disease and Related Disorders," was presented by Prof. Bradley Boeve (USA). Key highlights from this session include: • Why biomarker positivity alone can oversimplify disease biology — illustrated by patients with positive Alzheimer's biomarkers but very different syndromes and autopsy findings • How the predictive value of a positive biomarker depends heavily on age and pretest probability, a growing concern as blood-based tests reach beyond specialty clinics • Copathology as the rule rather than the exception in Alzheimer's, helping explain why symptoms, trajectories and treatment responses vary so widely • Neuropathology as an active field still defining new targets — from LATE, ARTAG and caspase-6-truncated tau to TMEM106B and annexin A11 pathologies • Evidence that neuromodulatory subcortical nuclei, including the locus coeruleus and orexinergic neurons, may be affected before the entorhinal cortex, reframing early neuropsychiatric symptoms as manifestations of the earliest biology • REM sleep behavior disorder (RBD) as a prodromal synucleinopathy, present in roughly 80–85% of dementia with Lewy bodies and often preceding other features by years or decades • Data showing about 80% of individuals with isolated RBD phenoconvert to Parkinson's disease, DLB or MSA within 14 years, though timing and phenotype remain unpredictable • The state-dissociation framework linking DLB with narcolepsy, and the orexin system as a key stabilizer of the sleep-wake switch and a potential therapeutic target • Isolated RBD as one of the best windows for disease-modifying intervention, supported by longitudinal platforms such as NAPS, PPMI and the International RBD Study Group Together, these lectures established two complementary messages for clinicians and researchers: neuropathology remains essential for correct biological interpretation in the biomarker era, and sleep and subcortical systems may offer some of the earliest, most actionable signals of neurodegeneration in both Alzheimer's and Lewy body disease. This episode is particularly relevant for neurologists, neuroscientists, neuropathologists, sleep medicine specialists, translational scientists, clinical trialists, biomarker researchers, and biotech and pharma professionals working across Alzheimer's disease and synucleinopathies. This podcast was created using AI to provide a concise and insightful summary of an AD/PD™ 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to consult official conference materials for detailed information. The AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders took place March 17–21, 2026, in Copenhagen, Denmark. 🔗 https://adpd.kenes.com

Episode thumbnail for Moonshots and Milestones: Is the Future of Neurodegeneration Drug Discovery in Startups, Big Pharma, or Academia? AD/PD™ Session Spotlight

July 9, 2026

Moonshots and Milestones: Is the Future of Neurodegeneration Drug Discovery in Startups, Big Pharma, or Academia? AD/PD™ Session Spotlight

In this episode, we will cover the Fireside Debate "Moonshots and Milestones: Is the Future of Neurodegeneration Drug Discovery in Startups, Big Pharma, or Academia?" that took place on March 17, 2026 at the AD/PD™ 2026 International Conference. The debate was moderated by Dr. Henrietta Nielsen (Sweden) and Prof. Philip Scheltens (Netherlands), with expert contributions from Dr. Geoffrey Kerchner (Switzerland), Prof. Cynthia Lemere (USA), Dr. Mark Mintun (USA), Dr. Marco Prado (Canada), and Prof. Niranjan Bose (USA). Key highlights from this session include:• The field has moved from repeated uncertainty to cautious optimism, anchored by disease-modifying anti-amyloid therapies that demonstrably slow Alzheimer's progression• Acceptance of biological heterogeneity in dementia, and how biomarker-driven stratification has reshaped diagnosis and trial design• The persistent gap between biomarker change and clinically meaningful outcomes, with cognition, function and independence remaining the endpoints that matter most• Blood-based biomarkers as potentially transformative for moving diagnosis beyond specialist centers into neurology clinics and primary care• Complementary views on the field's bottlenecks — surrogate endpoints and recruitment for industry, funding and slow translation for academia, outdated cognitive tools, and fragmented data infrastructure• The growing role of AI, multimodal data and data harmonization, alongside recognition that neurodegeneration still lags other fields in deploying AI• Strong support for combination therapy, with anti-amyloid treatment as an anchor and tau-directed or anti-inflammatory strategies layered on top• A closing consensus on the ideal ecosystem: openness, cross-sector collaboration, data sharing, smarter enrollment, sustained patient engagement, and support for early-career investigators The panel conveyed that disease modification is now real but still modest, that blood-based biomarkers are poised to reshape diagnostic and treatment pathways, and that future progress will depend on combination approaches, better surrogate markers, and coordinated collaboration across the neurodegeneration ecosystem. Encouragingly, participants agreed the next breakthrough should not take another 25 years — the field now has working therapies, sharper tools, and better biological resolution than ever before. This episode is particularly relevant for neurologists, clinical trialists, translational scientists, biotech and pharma professionals, academic researchers, data and AI experts, and patient advocacy leaders working across the neurodegenerative disease landscape.This podcast was created using AI to provide a concise and insightful summary of an AD/PD™ 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to consult official conference materials for detailed information.The AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders took place March 17–21, 2026, in Copenhagen, Denmark.🔗 https://adpd.kenes.com

January 16, 2026

Drug Development & Biomarkers in Rare CNS Diseases, AD/PD™ Session Spotlight

In this episode, we spotlight Forum Discussion 08 from the AD/PD™ 2025 International Conference — “Drug Development & Biomarkers in Rare CNS Diseases (ALS, FTD) from Basics to Approval – How to Define Success.” The discussion was moderated by Prof. Angela Genge (Canada) and Prof. Laura Ranum (USA), with expert contributions from Dr. Francesca Cignarella (USA), Prof. Guy Rouleau (Canada), Dr. Toby Ferguson (USA), and Prof. Patrick Weydt (Germany). Key highlights from this session include: • Advances in drug development for rare neurodegenerative diseases, with a focus on ALS and frontotemporal dementia (FTD)• Lessons learned from antisense oligonucleotide therapies, including SOD1-targeting approaches that have shown meaningful clinical impact in ALS• The growing importance of genetic stratification, enabling earlier and more targeted intervention in both symptomatic and presymptomatic individuals• How insights from related disorders, such as Huntington’s disease, are informing biomarker development, including the interpretation of neurofilament signals• The critical role of biomarkers in guiding clinical trials, measuring disease-relevant outcomes, and accelerating regulatory approval• The power of public–private partnerships, exemplified by initiatives such as the ALS Accelerating Medicines Partnership• The need for data sharing, collaboration, and patient involvement to overcome the challenges inherent in rare disease research• New infrastructure efforts, including the upcoming ALS Knowledge Platform, aimed at integrating data across studies to drive discovery The panel emphasized that success in rare CNS disease research requires not only scientific innovation, but also coordinated global collaboration, smarter trial design, and biomarkers that truly reflect disease biology. While challenges remain, the session conveyed strong optimism that genetics-driven approaches and shared data ecosystems will accelerate progress for ALS and FTD. This episode is particularly relevant for neurologists, translational researchers, clinical trialists, biotech and pharma professionals, patient advocacy leaders, and regulators working in rare neurodegenerative diseases. This podcast was created using AI to provide a concise and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to consult official conference materials for detailed information. The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders took place April 1–5, 2025, in Vienna, Austria.🔗 https://adpd.kenes.com

17 total episodes available

Deep-dive analytics for The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases?: AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer's, Parkinson’s, and related neurodegenerative diseases. The "AD/PD™ Session Spotlight" series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes.

Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.
How often does this podcast release new episodes?: This podcast updates daily.
Where can I listen to this podcast?: This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: No, this podcast does not typically feature guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.